

1 **Title:** A Novel Association Between Human Papillomavirus and Thyroid Eye Disease

2 **Authors:** *Ishita Garg, BS¹, *Benjamin I. Meyer, MD², Ryan A. Gallo, PhD¹, Sara T. Wester,
3 MD FACS^{1,2,†}, Daniel Pelaez, PhD^{1,2,†}

4 *Co-first authorship, †Co-corresponding

5 **Affiliations:**

6 ¹Dr. Nasser Al-Rashid Orbital Vision Research Center, McKnight Vision Research Center, University of Miami
7 Miller School of Medicine, Miami, FL USA

8 ²Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine,
9 Miami, FL USA

10 **Keywords:** thyroid eye disease, human papillomavirus, autoimmune, ELISA, Graves' disease

11 **Correspondence:**

12 Daniel Pelaez, PhD

13 1638 NW 10th Ave

14 Miami, FL 33136

15 dpelaez@med.miami.edu

16

Sara T. Wester, MD

900 NW 17th Street

Miami, FL 33136

swester2@med.miami.edu

17 **Acknowledgements/Funding:** This work was supported in part by the Dr. Nasser Al-Rashid

18 Orbital Research Endowment (Miami, FL, USA). Bascom Palmer Eye Institute is supported by

19 NIH Center Core Grant P30EY014801 and a Research to Prevent Blindness Unrestricted Grant

20 (New York, NY, USA).

21 **Disclosures:** None.

22 **Short Title:** Thyroid Eye Disease and HPV

23 **Word Count:** 2079

24 **Data Availability:** All datasets generated and analyzed during the current study are not publicly

25 available but are available from the corresponding author on reasonable request.

26 *This work is original and has not been previously published.*

27

28 **ABSTRACT**

29 **Context:** Thyroid eye disease (TED) is an autoimmune disease characterized by orbital
30 inflammation and tissue remodeling. TED pathogenesis is poorly understood but is linked to
31 autoantibodies to thyroid-stimulating hormone receptor (TSHR) and insulin-like growth factor 1
32 receptor (IGF-1R).

33 **Objective:** To explore the potential involvement of viral infections in TED pathogenesis.

34 **Methods:** Using NCBI BLAST, we compared human TSHR and IGF-1R proteins to various
35 viral proteomes, including *Papillomaviridae*, *Paramyxoviridae*, *Herpesviridae*, *Enterovirus*,
36 *Polyomaviridae*, and *Rhabdoviridae*. Enzyme-linked immunoassays (ELISAs) were performed
37 on orbital adipose tissue samples from 22 TED patients and controls to quantify antiviral
38 antibody titers. Demographics and clinical data were reviewed.

39 **Results:** Homology analysis revealed conserved motifs between TSHR and IGF-1R with several
40 viral proteins, particularly the human papillomavirus 18 (HPV18) L1 capsid protein. Basic
41 demographic and clinical information between the cohorts were comparable. ELISAs showed
42 statistically significant differences in the average HPV18 L1 IgG normalized optical density
43 levels among tissues of control ($M = 0.9387$, $SD = 0.3548$), chronic TED ($M = 2.305$, $SD =$
44 1.064), and active acute TED ($M = 4.087$, $SD = 2.034$) patients. These elevated HPV18 L1 IgG
45 titers did not statistically correlate with TSH, T4, or TSI levels, and were elevated in TED
46 patients irrespective of treatment with teprotumumab, indicating a direct immunological response
47 to HPV.

48 **Conclusions:** This study presents the first molecular evidence linking HPV and TED,
49 highlighting molecular mimicry between HPV capsid protein and key autoimmunity targets in

50 TED. This suggests an immunological link contributing to TED's pathogenesis, opening new
51 avenues for understanding and managing the disease.

52

53 **Introduction**

54 Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy or Grave's
55 orbitopathy, poses a unique clinical challenge for endocrinologists managing systemic thyroid
56 disease. It is characterized by an intricate interplay of autoimmune mechanisms targeting orbital
57 tissues, resulting in debilitating symptoms such as proptosis, diplopia, pain, dry eyes, and redness
58 [1, 2]. In its most severe form, TED can lead to compressive optic neuropathy, potentially
59 causing irreversible vision loss [3]. The incidence of TED in dysthyroid patients varies, ranging
60 from 25% to 50% of individuals with Graves' disease (GD) and approximately 3% to 5% of
61 those with Hashimoto's thyroiditis] [4, 5]. TED can also occur in euthyroid and, less commonly,
62 hypothyroid patients [2]. What predisposes an individual to develop TED and what leads to the
63 heterogeneity in clinical manifestations is largely unknown and a subject of significant clinical
64 interest. A better understanding of risk factors for the development of TED in patients with
65 systemic thyroid dysfunction would enable better screening, risk modification, and improved
66 therapeutic management earlier in the disease.

67 TED is often classified into two distinct clinical phases: an active phase, marked by
68 vasodilation, orbital congestion, and inflammation, and an inactive phase characterized by
69 fibrosis and a potentially reduced responsiveness to therapeutic interventions [6]. The approval
70 of teprotumumab, a monoclonal antibody targeting the Insulin-like Growth Factor-1 Receptor
71 (IGF-1R), by the FDA in 2020 represented a significant advancement in TED management,
72 demonstrating the effectiveness of targeted biological treatments [7]. The phase 2 and phase 3

73 clinical trials for teprotumumab were conducted with patients with active, inflammatory TED,
74 however recent studies have shown that teprotumumab reduces proptosis in patients with non-
75 inflammatory TED as IGF-1R is overexpressed on fibroblasts in both the inflammatory and non-
76 inflammatory phases [8]. Despite this progress, ongoing clinical trials continue to investigate
77 various pharmacological agents designed to modulate the autoimmune and inflammatory
78 pathways implicated in TED, in pursuit of more comprehensive therapeutic options.

79 The persistent gaps in our understanding of TED's pathogenesis, especially regarding the
80 factors influencing its onset and progression, underscore the necessity for further exploration into
81 its underlying mechanisms. Although the majority of TED cases are related to GD, with
82 documented upregulation of IGF-1R and Thyroid-Stimulating Hormone Receptor (TSHR) by
83 autoantibodies, the occurrence of TED in patients without apparent thyroid dysfunction suggests
84 that additional mechanisms beyond direct thyroid autoimmunity may be involved in its
85 development [2, 3].

86 Emerging insights into the nature of autoimmune diseases have illuminated the potential
87 role of molecular mimicry, a process where external pathogens trigger autoimmune responses by
88 presenting antigens that resemble host tissues [9]. This concept introduces the hypothesis that
89 infections may act as catalysts for autoimmune conditions like TED through a process that is not
90 yet fully understood, suggested by reports of new onset TED following COVID-19 infection
91 [10]. This study seeks to explore the hypothesis that an infectious agent may underlie the
92 pathogenesis of TED, leveraging mechanisms of molecular mimicry which then may initiate or
93 exacerbate the disease process.

94

95 **Materials and Methods**

96 *Homology Search*

97 A protein homology analysis was conducted using the National Center for Biotechnology
98 Information (NCBI) Basic Local Alignment Search Tool (BLAST) to compare the human IGF-
99 1R isoform 1 precursor protein (NP_000866.1) and the human TSHR isoform 1 precursor protein
100 (NP_000360.2) with various viral proteomes.

101

102 *Participants and Specimen Collection*

103 The University of Miami Institutional Review Board approved this study (IRB
104 20110692). This study adhered to the tenets of the Declaration of Helsinki. Orbital adipose tissue
105 was collected from the medial fat of upper or lower eyelids in control patients undergoing
106 blepharoplasty or TED patients undergoing orbital decompression surgery at the Bascom Palmer
107 Eye Institute (Miami, FL). Eleven control patients and eleven patients with TED were included
108 in this study.

109

110 *Orbital Adipose Sample Processing*

111 Orbital adipose samples were cut into smaller sections and washed with 1X phosphate
112 buffered saline (PBS). Orbital adipose samples weighing between 60 to 110 mg were used for
113 downstream processing. To obtain protein lysates from the tissues, a Branson 450 Digital
114 Sonifier was used at the following settings: a duty cycle of two seconds on/three seconds off for
115 40 seconds at 40% amplitude. The sample was then centrifuged for ten minutes at 14,000 x g and
116 the supernatant was collected. Samples were stored in -80°C until further use.

117

118 *Measurement of HPV18 L1 IgG*

119 A detergent-compatible (DC) protein assay (Catalog # 5000112) was performed to
120 determine protein concentration in the processed samples. Protein concentrations were
121 normalized to the lowest concentration. Based on BLAST results, the Papillomavirus type 18 L1-
122 Capsid Antibody (IgG) enzyme-linked immunosorbent assay (ELISA; Catalog # NBP2-60106-
123 1Kit, RRID: AB_3095886) was performed to measure human papillomavirus 18 L1 capsid
124 protein (HPV18L1) IgG levels by optical density (OD) in control and TED patient samples.
125 Higher OD corresponded to increased light absorption by the sample, reflective of a higher
126 antibody antigen/antibody concentration. The protocol was followed as directed by the
127 manufacturer.

128

129 *Clinical Summary*

130 Clinical data were extracted from patient records. Patient demographics and clinical
131 history were reviewed including age, gender, smoking status, thyroid-stimulating hormone
132 (TSH), thyroxine (T4), and thyroid-stimulating immunoglobulin (TSI) levels, and Clinical
133 Activity Score (CAS). The 7-point CAS scale was used.

134

135 *Statistical Analysis*

136 To calculate the normalized OD (to account for the variable avidities, i.e. number of
137 binding sites, of different antibodies), the sample OD value was divided by the geometric mean
138 of the control samples as per ELISA manufacturer instructions. Statistical analyses were
139 computed using GraphPad Prism 10.0.2 (La Jolla, California). The one-way ANOVA with the
140 post-hoc Tukey test or unpaired T test were performed to identify differences between the means
141 of the study groups. Pearson correlation analyses with two-tailed p values were performed.

142

143 **Results**

144 *Homology Between IGF-1R/TSHR and HPV Major L1 Capsid*

145 BLAST homology analysis identified several homologous short sequences between
146 human IGF-1R and TSHR with various proteomic components within the following viral
147 proteome assemblies: *Papillomaviridae*, *Paramyxoviridae*, *Herpesviridae*, *Enteroviruses*,
148 *Polyomaviridae*, and *Rhabdoviridae*. There were many similarities between human IGF-1R and
149 TSHR with internal and viral matrix proteins, or to proteins encoded by the viral genome which
150 are expressed in the cytoplasm of infected host cells, which deprioritized these proteins as
151 significant antigenic triggers. However, there were homologous alignments between human IGF-
152 1R/TSHR with the major capsid proteins of the human *Papillomaviridae* family. Notably, two
153 motifs from the HPV L1 capsid protein were highly conserved across all human papillomavirus
154 serotypes and human IGF-1R and TSHR sequences: FGXV and IXEXT+NP (**Fig. 1**).

155

156 *Clinical Summary*

157 The demographic and clinical characteristics of the patient cohort are outlined in **Table 1**.
158 22 patients were included in this study (11 controls and 11 with TED). Acute disease activity was
159 defined as CAS \geq 4 for less than 12 months; chronic disease was defined as lasting more than 12
160 months. Inactive disease was defined by patients with a CAS < 3. Of the patients with TED, 7
161 individuals had chronic disease and 4 individuals had acute active disease. Most patients were
162 female: 10 (10/11; 90.9%) in the control, 6 (6/7; 85.7%) in the chronic TED, and 3 (3/4; 75%) in
163 the acute active TED groups. Mean ages at the time of surgery were 63.02 years (range: 54-
164 70.6), 52.66 years (range: 37.4-74.4), and 63.73 years (range: 49.4-69.8) for control, chronic

165 TED, and acute active TED patients, respectively. When comparing chronic versus acute active
166 TED patients, no statistically significant differences emerged in TSH ($p = 0.6862$), T4 ($p =$
167 0.742), and TSI levels ($p = 0.4931$). The average highest CAS score for chronic TED patients
168 was 3 ± 2.236 while the average highest CAS score for acute active TED patients was $5.25 \pm$
169 0.9574 .

170

171 *Increased anti-HPV18 L1 IgG Titers in Chronic and Active TED Patients*

172 Based on the results from the BLAST homology search, we next measured IgG antibody
173 titers against HPV18 L1 capsid protein by ELISA in orbital adipose tissue from the control and
174 TED patients. The mean normalized optical densities of human HPV18 L1 IgG antibody in the
175 orbital adipose tissues were 0.9387 ± 0.3548 , 2.305 ± 1.064 , and 4.087 ± 2.034 from the control,
176 chronic TED, and acute active TED groups, respectively. These mean concentrations were
177 significantly different between control and chronic TED patients ($p = 0.0344$), control and active
178 acute TED patients ($p = 0.0001$), and chronic and active acute TED patients ($p = 0.0333$) (**Fig.**
179 **2a**). There was no significant evidence for correlations between orbital adipose tissue HPV18L1
180 IgG valency with TSH levels, T4 levels, or TSI levels in either chronic or acute active TED
181 patients (**Fig. 2b; Table 2**).

182 To parse out potential effects of teprotumumab intervention in TED patients on IgG
183 HPV18 L1 valency, we performed subgroup analysis (**Fig. 2c**). No significant difference was
184 noted comparing treated versus non-treated patients (Student T test). Further analyses did not
185 reveal statistically significant differences between antibody titers in patients when comparing
186 between radioactive iodine treatment or prior thyroidectomy (**Supplemental Fig 2**).

187

188 **Discussion**

189 This study presents molecular evidence suggesting a novel association between HPV and
190 TED, facilitated potentially through molecular mimicry between the HPV's L1 capsid protein
191 and significant autoimmunity targets in TED, specifically IGF-1R and TSHR. The discovery of
192 significantly elevated IgG antibodies against the HPV L1 capsid protein in patients with chronic
193 and active TED—irrespective of treatment with teprotumumab—highlights a potential
194 immunological connection that may play a crucial role in TED's pathogenesis.

195 The *Papillomaviridae* family encompasses over 150 HPV subtypes, with types 16 and 18
196 being primary culprits in cervical cancers [11]. Molecular mimicry has been implicated in
197 various autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus
198 (SLE), Sjogren's syndrome, autoimmune liver disease, inflammatory bowel disease, and multiple
199 sclerosis [12]. This phenomenon has also been proposed to explain the rare occurrences of
200 autoimmune disease activation or flares following vaccination; however, such data are scarce and
201 sometimes conflicting, necessitating cautious interpretation to avoid potential confounders or the
202 mistaken extrapolation of correlation for causation [13-16].

203 The question of molecular mimicry's role in TED through HPV infection introduces a
204 new dimension to this discussion. Research indicates that individuals with SLE not only show
205 higher rates of high-risk HPV infections but also an increased risk of cervical dysplasia, likely
206 due to immunosuppression [17, 18]. This suggests that an underlying autoimmune or
207 inflammatory state may elevate HPV susceptibility. Moreover, a retrospective study of 62
208 patients highlighted a significant association between HPV infection and autoimmune disorders,
209 with a 20% prevalence of autoimmune disease in HPV DNA-positive women versus

210 approximately 3% in the general population, alongside increased autoantibody levels,
211 underscoring the complex link between HPV and autoimmunity [19].

212 The widespread vaccination against high-risk HPV strains, aimed at preventing cervical
213 cancer, has yielded substantial data for analysis, particularly in young women who are more
214 susceptible to autoimmune diseases due to hormonal changes during puberty [20]. Currently,
215 three HPV vaccines are in use: Cervarix (bivalent), Gardasil (quadrivalent), and Gardasil9
216 (nonavalent) [11]. A significant study by Jacobsen et al., involving nearly 190,000 vaccinated
217 young women, reported six new cases of Graves' disease post-vaccination with the quadrivalent
218 vaccine [21]. However, in a separate study this group found no pattern of autoimmune diseases
219 related to vaccine timing, dosage, or patient age, suggesting that the observed autoimmune
220 thyroid cases might have pre-existed vaccination, as indicated by a non-elevated incidence rate
221 ratio (IRR=0.72 [0.50-1.01]) upon detailed review [22].

222 The quadrivalent HPV vaccine, which leverages virus-like particles from the HPV L1
223 capsid protein, aims to replicate the HPV virus's structure to stimulate a suitable immune
224 response [23, 24]. Our findings show a homology between the HPV L1 capsid protein and key
225 TED autoimmunity targets (IGF-1R and TSHR), suggesting potential autoimmune disease
226 triggers from HPV L1 protein exposure or vaccination. Yet, prior extensive analyses, including a
227 systematic review and meta-analysis of over 169,000 autoimmune disorder cases, indicated no
228 significant risk increase for autoimmune diseases post-HPV vaccination (odds ratio 1.003) [25].
229 This suggests HPV vaccination is safe and unlikely to directly initiate autoimmune disease,
230 though it may reveal pre-existing autoimmune conditions, necessitating further research. These
231 insights highlight the need to differentiate the effects of natural HPV infection from vaccination

232 outcomes in TED research, ensuring that vaccine-induced autoimmunity is not mistakenly
233 implicated or deduced.

234 The higher prevalence of both HPV and TED in females, contrasted with more severe
235 disease manifestations in males, raises intriguing questions about sex-specific immune responses
236 and hormonal influences on disease severity and progression [26]. This sex disparity could
237 provide critical insights into the underlying mechanisms of HPV's impact on TED, highlighting
238 an area ripe for further investigation.

239 Our study faces several limitations, including a small sample size and an imbalance in
240 male-to-female ratios (albeit reflective of natural demographic differences), which may affect the
241 generalizability of our findings. Additionally, the absence of detailed clinical histories regarding
242 prior HPV infection or vaccination status among participants limits our ability to fully
243 understand the relationship between HPV exposure and TED development.

244 Despite these limitations, our findings offer a groundbreaking perspective on TED's
245 association with HPV through molecular mimicry, establishing a foundation for subsequent,
246 more definitive research. This exploratory study serves as a catalyst for future investigations to
247 confirm the causative link between HPV and TED, potentially revolutionizing our approach in
248 managing this complex autoimmune condition.

249 **References:**

- 250 1. Ugradar, S., et al., *Teprotumumab for the treatment of chronic thyroid eye disease*. Eye
251 (Lond), 2022. **36**(8): p. 1553-1559.
- 252 2. Hoang, T.D., et al., *2022 Update on Clinical Management of Graves Disease and Thyroid*
253 *Eye Disease*. Endocrinol Metab Clin North Am, 2022. **51**(2): p. 287-304.
- 254 3. Hodgson, N.M. and F. Rajaii, *Current Understanding of the Progression and Management*
255 *of Thyroid Associated Orbitopathy: A Systematic Review*. Ophthalmol Ther, 2020. **9**(1): p.
256 21-33.
- 257 4. Bartalena, L. and M.L. Tanda, *Clinical practice. Graves' ophthalmopathy*. N Engl J Med,
258 2009. **360**(10): p. 994-1001.
- 259 5. Perros, P., et al., *Graves' orbitopathy as a rare disease in Europe: a European Group on*
260 *Graves' Orbitopathy (EUGOGO) position statement*. Orphanet J Rare Dis, 2017. **12**(1): p.
261 72.
- 262 6. Bothun, E.D., et al., *Update on thyroid eye disease and management*. Clin Ophthalmol,
263 2009. **3**: p. 543-51.
- 264 7. Fernando, R., O. Caldera, and T.J. Smith, *Therapeutic IGF-I receptor inhibition alters*
265 *fibrocyte immune phenotype in thyroid-associated ophthalmopathy*. Proc Natl Acad Sci U
266 S A, 2021. **118**(52).
- 267 8. Ugradar, S., et al., *Teprotumumab for non-inflammatory thyroid eye disease (TED):*
268 *evidence for increased IGF-1R expression*. Eye (Lond), 2021. **35**(9): p. 2607-2612.
- 269 9. Martins, Y.C., A.D. Jurberg, and C.T. Daniel-Ribeiro, *Visiting Molecular Mimicry Once*
270 *More: Pathogenicity, Virulence, and Autoimmunity*. Microorganisms, 2023. **11**(6).
- 271 10. Allam, M.M., et al., *Thyroid disease and covid-19 infection: Case series*. Clin Case Rep,
272 2021. **9**(6): p. e04225.
- 273 11. Kombe Kombe, A.J., et al., *Epidemiology and Burden of Human Papillomavirus and*
274 *Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation*. Front Public Health,
275 2020. **8**: p. 552028.
- 276 12. Maoz-Segal, R. and P. Andrade, *Molecular Mimicry and Autoimmunity*. Infection and
277 Autoimmunity, 2015: p. 6.
- 278 13. Shan, J., et al., *COVID-19 vaccination and the risk of autoimmune diseases: a Mendelian*
279 *randomization study*. Front Public Health, 2024. **12**: p. 1322140.
- 280 14. Kim, H.J., et al., *Autoimmune adverse event following COVID-19 vaccination in Seoul,*
281 *South Korea*. J Allergy Clin Immunol, 2024.
- 282 15. Acharya, I., et al., *Reactive Arthritis After mpox Vaccination*. J Community Hosp Intern
283 Med Perspect, 2024. **14**(1): p. 35-38.
- 284 16. Lim, S.H., et al., *Autoimmune and Autoinflammatory Connective Tissue Disorders*
285 *Following COVID-19*. JAMA Network Open, 2023. **6**(10): p. e2336120-e2336120.
- 286 17. Tam, L.S., et al., *Natural history of cervical papilloma virus infection in systemic lupus*
287 *erythematosus - a prospective cohort study*. J Rheumatol, 2010. **37**(2): p. 330-40.
- 288 18. Santana, I.U., et al., *Systemic lupus erythematosus, human papillomavirus infection,*
289 *cervical pre-malignant and malignant lesions: a systematic review*. Clin Rheumatol, 2011.
290 **30**(5): p. 665-72.

- 291 19. Donmez, H.G., et al., *Human papillomavirus infection and autoimmune disorders: a*
292 *tertiary center experience*. *Pathogens and Disease*, 2019. **77**(3).
- 293 20. Desai, M.K. and R.D. Brinton, *Autoimmune Disease in Women: Endocrine Transition and*
294 *Risk Across the Lifespan*. *Front Endocrinol (Lausanne)*, 2019. **10**: p. 265.
- 295 21. Jacobsen, S.J., et al., *An unmasking phenomenon in an observational post-licensure*
296 *safety study of adolescent girls and young women*. *Vaccine*, 2012. **30**(31): p. 4585-7.
- 297 22. Chao, C., et al., *Surveillance of autoimmune conditions following routine use of*
298 *quadrivalent human papillomavirus vaccine*. *J Intern Med*, 2012. **271**(2): p. 193-203.
- 299 23. Akuzum, B., et al., *L1 Recombinant Proteins of HPV Tested for Antibody Forming Using*
300 *Sera of HPV Quadrivalent Vaccine*. *Immune Netw*, 2018. **18**(3): p. e19.
- 301 24. CDC. *HPV Vaccine*. November 16 2021 [cited 2024 March 31].
- 302 25. Jiang, H.-y., et al., *Human papillomavirus vaccination and the risk of autoimmune*
303 *disorders: A systematic review and meta-analysis*. *Vaccine*, 2019. **37**(23): p. 3031-3039.
- 304 26. Manji, N., et al., *Influences of age, gender, smoking, and family history on autoimmune*
305 *thyroid disease phenotype*. *J Clin Endocrinol Metab*, 2006. **91**(12): p. 4873-80.
- 306

307

308

309

310

311

312

313

314

315

316

317


318

319

320


321

322 **Figure 1. BLAST homology search.** Protein homology analysis was conducted using the
 323 National Center for Biotechnology Information Basic Local Alignment Search Tool (BLAST)
 324 between the human insulin-like growth factor 1 receptor, isoform 1 precursor (accession #
 325 NP_000866.1) and the human thyrotropin receptor isoform 1 precursor (accession #
 326 NP_000360.2) against the following viral proteome assemblies: *Papillomaviridae*,
 327 *Paramyxoviridae*, *Herpesviridae*, *Enteroviruses*, *Polyomaviridae*, *Rhabdoviridae*. Shown here
 328 are the protein motifs (shown in green, purple, and blue) from the HPV L1 capsid protein that are
 329 highly conserved across all human papillomavirus serotypes and returned high alignment
 330 correlations to motifs in the human IGF-1R and TSHR (x = any amino acid; + = similarly
 331 charged amino acid; ψ = hydrophobic amino acid).





		FGxVY																														
IGF1R	NP_000866.1	...	S	-	D	-	V	-	W	-	S	-	F	-	G	-	V	-	V	-	L	-	W	-	E	-	I	-	A	-	T	...
TSHR	NP_000360.2	...	I	-	D	-	K	-	D	-	A	-	F	-	G	-	G	-	V	-	Y	-	S	-	G	-	P	-	S	-	L	...
HPVL1	AAC63359.1	...	L	-	D	-	E	-	W	-	N	-	F	-	G	-	V	-	V	-	P	-	P	-	P	-	S	-	T	-	S	...
		IxExT+NP / T+NP																														
IGF1R	NP_000866.1	...	D	-	I	-	E	-	E	-	V	-	T	-	E	-	N	-	P	-	K	-	T	-	E	-	V	-	C	...		
TSHR	NP_000360.2	...	F	-	I	-	L	-	E	-	I	-	T	-	D	-	N	-	P	-	Y	-	M	-	T	-	S	-	I	...		
HPVL1	AYA94205.1	...	N	-	K	-	L	-	N	-	D	-	T	-	E	-	N	-	P	-	N	-	Q	-	Y	-	F	-	T	...		
	AYA94205.1	...	S	-	I	-	P	-	E	-	V	-	H	-	E	-	N	-	P	-	A	-	T	-	K	-	Y	-	V	...		
		MA Ψ L																														
IGF1R	NP_000866.1	...	E	-	I	-	A	-	D	-	G	-	M	-	A	-	Y	-	L	-	N	-	A	-	N	-	K	-	F	...		
TSHR	NP_000360.2	...	K	-	I	-	A	-	K	-	R	-	M	-	A	-	V	-	L	-	I	-	F	-	T	-	D	-	F	...		
HPVL1	AAC63359.1	...	L	-	T	-	P	-	E	-	V	-	M	-	A	-	Y	-	L	-	H	-	T	-	M	-	N	-	E	...		

333 **Figure 2a: Human papillomavirus 18 L1 capsid protein (HPV18L1) IgG levels orbital fat**
334 **samples.** P value denoted by: * is ≤ 0.05 ; ** is ≤ 0.01 ; *** is ≤ 0.001 .




335
336 **Figure 2b: Subgroup analysis comparing thyroid status with HPV18L1 IgG levels.** TSH =
337 thyroid stimulating hormone. Normalized OD₄₅₀ is the normalized optical density absorbability
338 as the metric for antibody titer based on the enzyme-linked immunosorbent assay (ELISA)



339

340



341

342

343 **Figure 2c: Impact of teprotumumab treatment on HPV18L1 IgG levels.** Tepro =

344 teprotumumab. P value denoted by: * is ≤ 0.05 ; ns: not significant.

345

346

347

348

349

350

351

352

353


354

355

356

357

358



359 **Table 1: Patient Characteristics**

	Control (n = 11)	Chronic TED (n = 7)	Acute Active TED (n = 4)
Age (Mean)	63.02	52.66	56.73
Range	54-70.6	37.4-74.4	49.4-69.8
<hr/>			
Sex			
Female	10	6	3
Male	1	1	1
TSH		1.157 ± 1.538	0.8145 ± 0.6304
Free T4		1.396 ± 0.3023	1.46 ± 0.1510
<hr/>			
Smoking			
Never	9	4	4
Former	1	3	0
Current	1	0	0
CAS			
Highest		3 ± 2.236	5.25 ± 0.9574
Range		1-7	4-6
HPV Valency	0.9387 ± 0.3548	2.305 ± 1.064	4.087 ± 2.034

360

361

362 **Table 2: HPV18L1 IgG Titer Subgroup Analysis**

	Chronic TED (n = 7)		Acute Active TED (n = 4)	
	Correlation coefficient	P value	Correlation coefficient	P value
TSH level	-0.5000	0.2667	0.8000	0.3333
T4 level	0.2536	0.5832	-0.9617	0.1768
TSI level	-0.6725	0.2136	-0.1543	0.9014

363

364


365

366 **Supplemental Figures:**

367 **Supplemental Figure 1. Subgroup analysis of teprotumumab treatment and thyroid eye**

368 **disease status with HPV18L1 IgG levels.**

369



370

371

372

373

374

375

376

377


378

379

380

381 **Supplemental Figure 2. Impact of thyroid treatment on HPV18L1 IgG levels.**

382



383